<DOC>
	<DOCNO>NCT01429987</DOCNO>
	<brief_summary>This randomize , double-blind , placebo control , 12 week repeat oral dose , dose range study determine efficacy safety 3 dos plecanatide compare placebo patient Chronic Idiopathic Constipation ( CIC ) .</brief_summary>
	<brief_title>The Plecanatide Chronic Idiopathic Constipation ( CIC ) Study</brief_title>
	<detailed_description>This Phase IIb/III , randomize , double-blind , placebo-controlled , 12-Week , Repeat , Oral Dose Ranging , study determine safety efficacy plecanatide patient chronic idiopathic constipation ( CIC ) . Subjects diagnose CIC via modify Rome III criterion screen inclusion exclusion criterion study enter 2 Week pre treatment screen . During phase patient require call bowel movement ( BM diary ) occur , call least daily complete patient diary question symptom ( Symptom Diary ) associate CC , throughout trial . Patients complete least 5 day dose per week , 6 7 day period BM diary call , continue less 3 complete spontaneous movement per week ( well meet inclusion exclusion criterion ) enrol randomized one three plecanatide dose 0.3 mg , 1.0 mg , 3.0 mg placebo . 880 patient randomized intent 200 patient per treatment group ( group size ) include efficacy analysis . All subject receive least one dose plecanatide match placebo include safety analysis .</detailed_description>
	<mesh_term>Constipation</mesh_term>
	<criteria>Male female age 1875 , inclusive Body Mass Index = 1835 kg/m2 , inclusive Meets modify Rome III criterion functional chronic idiopathic constipation least 3 month symptom onset least 6 month . Note : For trial , patient manual maneuver require &gt; 25 % defecation eligible participation . Less 3 CSBMs per week baseline pretreatment Completed colonoscopy accordance medical guideline appropriate , clinically significant finding Patient willing discontinue use supplemental fiber , laxatives , prescription nonprescription medication , herbal dietary supplement intend treat constipation screening , pretreatment , treatment 2week posttreatment period Willing maintain stable diet study . Patients hemorrhoids and/or diverticulosis ( NOT diverticulitis ) CAN enter study . Loose stool ( mushy ) watery ( Bristol score 6 7 ) stool absence laxative prohibit medicine &gt; 25 % BMs 3 month prior screen visit OR 14 day treatment period Patient meet Rome III criterion Irritable Bowel Syndrome ( IBSC ) Active peptic ulcer disease adequately treat stable History cathartic colon , laxative , enema abuse , ischemic colitis . Fecal impaction within 3 month screen Patient /has : disease condition associate constipation ( GI CNS ) , structural abnormality GI tract gastric bypass surgery , pelvic floor dysfunction , pseudoobstruction , active infectious gastritis , diverticulitis , anal fissure disease condition affect GI motility defecation associate abdominal pain Unexplained clinically significant `` alarm symptom '' include low GI bleeding , irondeficiency anemia , weight loss systemic sign infection colitis . Major surgery within 60 day screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Chronic Idiopathic Constipation</keyword>
	<keyword>Constipation</keyword>
	<keyword>Sign Symptoms : Digestive</keyword>
</DOC>